6 citations
,
January 2022 in “Journal of Investigative Dermatology”
Male pattern baldness is linked to higher levels of a certain receptor in the scalp, which leads to the shrinking of blood vessels and hair loss. Early treatment targeting this receptor could be more effective.
Balding scalps have more androgenreceptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgensignaling and TGF-beta may help prevent hair loss.
The conversation discusses topical androgenreceptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and AndrogenReceptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgenreceptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgenreceptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.